Frontotemporal Dementia News and Research

RSS

DNA drugs help restore the normal processing of protein-encoding RNA

A protein named TDP-43 has been lost from its normal location in the nucleus of the cell in virtually all persons having amyotrophic lateral sclerosis (ALS) and in up to half of all cases of frontotemporal dementia and Alzheimer’s disease (AD).

From UC San Diego 20 Mar 2023

Delaying paralysis in ALS by using designer DNA drug

In virtually all persons with amyotrophic lateral sclerosis (ALS) and in up to half of all cases of Alzheimer's disease (AD) and frontotemporal dementia, a protein called TDP-43 is lost from its normal location in the nucleus of the cell.

20 Mar 2023

Novel way to block the death of nerve cells in MND

Scientists have found a novel way to block the transportation of mutant RNA and subsequent production of toxic repeat proteins which lead to the death of nerve cells in the most common subtypes of motor neurone disease (MND) and frontotemporal dementia (FTD).

2 Mar 2023

RNA modification plays a vital role in TDP-43-related neurodegeneration in ALS

Nearly 100% of cases of amyotrophic lateral sclerosis-the progressive, fatal neurodegenerative disease known as ALS or Lou Gherig's disease-involve the buildup of a protein called TDP-43.

28 Feb 2023

Scientists discover two ways to preserve diseased upper motor neurons in ALS

Northwestern Medicine scientists have discovered two ways to preserve diseased upper motor neurons that would normally be destroyed in ALS, based on a study in mice. Upper motor neurons initiate movement, and they degenerate in ALS.

24 Feb 2023

WashU researcher receives NIH grant to study a poorly understood protein linked to ALS

The relentless neurological disease amyotrophic lateral sclerosis (ALS) eventually shuts down the entire body, but the devastation starts at a molecular level.

14 Feb 2023

RNA-targeting strategy to repair the genetic cause of ALS and dementia

Researchers at UF Scripps Biomedical Research have created a potential treatment for a major factor in the development of ALS and dementia that functions by removing disease-causing RNA segments.

24 Nov 2022

Researchers get funding to develop a vaccine against ALS disease

DZNE and Intravacc B.V., have received a grant from the European Union of € 2.5 million to further create a prototype ALS vaccine.

8 Jul 2022

Researchers analyze single-cell DNA sequencing for having a significant role in Alzheimer’s disease

The loss of functional neurons in the brain is a characteristic of Alzheimer’s disease. What, on the other hand, is the source of this loss?

21 Apr 2022

Critical signaling pathways in immune cells could reduce Alzheimer’s progression

According to Weill Cornell Medicine researchers, inhibiting a critical signaling route in brain-resident immune cells may reduce brain inflammation and hence halt the progression of the disease in Alzheimer’s and other neurodegenerative disorders.

15 Apr 2022

Novel molecular pathway shared by ALS and frontotemporal dementia identified

Scientists from two independent research teams have discovered how the mislocalization of a protein, known as TDP-43, alters the genetic instructions for UNC13A, providing a possible therapeutic target that could also have implications in treating amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other forms of dementia.

1 Mar 2022

Stanford study reveals how ribosomes may contribute to age-related diseases

Aging leads to a decline in cellular fitness and loss of optimal protein function. Many age-related ailments, including Alzheimer's and Parkinson's diseases, are caused by protein aggregation, a result of errors in protein folding.

20 Jan 2022

First molecular structure of TDP-43 could pave the way for new ALS therapies

Scientists have determined for the first time the structure of the molecule associated with amyotrophic lateral sclerosis (ALS) and multiple other neurodegenerative diseases.

9 Dec 2021

'Mini brains' allow researchers to study a fatal, untreatable neurological disorder

Cambridge researchers have developed 'mini brains' that allow them to study a fatal and untreatable neurological disorder causing paralysis and dementia – and for the first time have been able to grow these for almost a year.

22 Oct 2021

Study identifies variants and genes linked to alcohol consumption

Scientists from the Icahn School of Medicine at Mount Sinai published the first of its kind research in the field of addiction genetics employing a multi-omics method to offer a huge list of causal candidate genes linked with alcohol consumption and alcohol use disorder (AUD).

24 Aug 2021

Restoring cholesterol levels could be a new therapeutic approach for neurodegenerative diseases

Scientists have found that the brain lacks the ability to maintain the cholesterol-rich myelin sheath that insulates neurons when a protein is absent.

From National University of Singapore (NUS) 10 Aug 2021

New study could help develop novel treatments for neurodegenerative diseases

Researchers have introduced a novel gene therapy program that could set the stage for new treatments for neurodegenerative diseases.

2 Aug 2021

Single biomarker in the blood can accurately indicate underlying neurodegeneration

Levels of a protein called neurofilament light chain (NfL) in the blood can identify those who might have neurodegenerative diseases such as Down's syndrome dementia, motor neuron disease (ALS) and frontotemporal dementia, when clinical symptoms are not definitive.

8 Jun 2021

KAIST researchers identify mechanism underlying plasticity in adult brains

Developing brains constantly sprout new neuronal connections called synapses as they learn and remember. Important connections — the ones that are repeatedly introduced, such as how to avoid danger — are nurtured and reinforced, while connections deemed unnecessary are pruned away.

28 Dec 2020

Research projects receive BTCA awards to develop new drugs

Five research projects with exceptional promise to deliver new life-changing and health-altering therapies have received the inaugural Blavatnik Therapeutics Challenge Awards (BTCA) at Harvard Medical School.

From Harvard Medical School 30 Oct 2020